VDR and neoplasm: Acquired gefitinib-resistant NSCLCs upregulate their own VDR protein expression, which may induce CYP24A1 production and accelerate the catabolism of 1,25(OH)2D3, thereby suppressing the anti-tumor effects of 1,25(OH)2D3.